Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase
- PMID: 20160494
- DOI: 10.4161/cc.9.5.10935
Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase
Abstract
Checkpoint kinase 1 (Chk1) regulates cell cycle checkpoints and DNA damage repair in response to genotoxic stress. Inhibition of Chk1 is an emerging strategy for potentiating the cytotoxicity of chemotherapeutic drugs. Here, we demonstrate that AZD7762, an ATP -competitive Chk1/2 inhibitor induces gammaH2AX in gemcitabine-treated cells by altering both dynamics and stability of replication forks, allowing the firing of suppressed replication origins as measured by DNA fiber combing and causing a dramatic increase in DNA breaks as measured by comet assay. Furthermore, we identify ATM and DNA-PK, rather than ATR, as the kinases mediating gammaH2AX induction, suggesting AZD7762 converts stalled forks into double strand breaks (DSBs). Consistent with DSB formation upon fork collapse, cells deficient in DSB repair by lack of BRCA2, XRCC3 or DNA-PK were selectively more sensitive to combined AZD7762 and gemcitabine. Checkpoint abrogation by AZD7762 also caused premature mitosis in gemcitabine-treated cells arrested in G(1)/early S-phase. Prevention of premature mitotic entry via Cdk1 siRNA knockdown suppressed apoptosis. These results demonstrate that chemosensitization of gemcitabine by Chk1 inhibition results from at least three cellular events, namely, activation of origin firing, destabilization of stalled replication forks and entry of cells with damaged DNA into lethal mitosis. Additionally, the current study indicates that the combination of Chk1 inhibitor and gemcitabine may be particularly effective in targeting tumors with specific DNA repair defects.
Comment in
-
Targeting Chk1 in the replicative stress response.Cell Cycle. 2010 Mar 15;9(6):1025. doi: 10.4161/cc.9.6.11155. Epub 2010 Mar 15. Cell Cycle. 2010. PMID: 20237419 Free PMC article. No abstract available.
Similar articles
-
Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress.Nucleic Acids Res. 2012 Nov;40(21):10780-94. doi: 10.1093/nar/gks849. Epub 2012 Sep 12. Nucleic Acids Res. 2012. PMID: 22977173 Free PMC article.
-
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.Cancer Res. 2010 Jun 15;70(12):4972-81. doi: 10.1158/0008-5472.CAN-09-3573. Epub 2010 May 25. Cancer Res. 2010. PMID: 20501833 Free PMC article.
-
H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation.Mol Cancer Ther. 2007 Apr;6(4):1239-48. doi: 10.1158/1535-7163.MCT-06-0633. Epub 2007 Apr 3. Mol Cancer Ther. 2007. PMID: 17406032
-
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.Adv Cancer Res. 2010;108:73-112. doi: 10.1016/B978-0-12-380888-2.00003-0. Adv Cancer Res. 2010. PMID: 21034966 Review.
-
The ATR pathway: fine-tuning the fork.DNA Repair (Amst). 2007 Jul 1;6(7):953-66. doi: 10.1016/j.dnarep.2007.02.015. Epub 2007 May 24. DNA Repair (Amst). 2007. PMID: 17531546 Review.
Cited by
-
Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma.BMC Cancer. 2015 Jun 10;15:462. doi: 10.1186/s12885-015-1474-8. BMC Cancer. 2015. PMID: 26054341 Free PMC article.
-
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.Clin Cancer Res. 2023 Jan 17;29(2):331-340. doi: 10.1158/1078-0432.CCR-22-2074. Clin Cancer Res. 2023. PMID: 36378548 Free PMC article. Clinical Trial.
-
Increased transcription in hydroxyurea-treated root meristem cells of Vicia faba.Protoplasma. 2013 Feb;250(1):251-9. doi: 10.1007/s00709-012-0402-x. Epub 2012 Apr 15. Protoplasma. 2013. PMID: 22526201 Free PMC article.
-
Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.Clin Cancer Res. 2011 Jun 1;17(11):3706-15. doi: 10.1158/1078-0432.CCR-10-3082. Epub 2011 Apr 11. Clin Cancer Res. 2011. PMID: 21482692 Free PMC article.
-
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy.Mol Cell Oncol. 2015 Feb 23;2(4):e1012976. doi: 10.1080/23723556.2015.1012976. eCollection 2015 Oct-Dec. Mol Cell Oncol. 2015. PMID: 27308506 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous